← All candidates
No insider filings on record.
12 filings on record.
ENGNenGene Therapeutics Inc.
NasdaqCM · Healthcare · $120.63M
$1.80
+1.07% · Sep 15
No insider filings on record.
enGene Therapeutics Inc. hasn't reported Form 4 activity yet.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$120.63M
Float
32.7M
49% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
4 filingsnewest first
The record
newest first
No insider transactions on file for ENGN yet.
Context
Wall St
$3.29 avg target
+82.5% vs today · 7 analysts · consensus Hold
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 3 quarters beat
Q3 '26−$0.47 act−$0.04
Q1 '26−$0.44 act+$0.13
Q3 '25−$0.57 act−$0.06
Coverage
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer MarketMarketBeat · 08-13Neumora depression drug fails; EnGene to cut 50% of staffBioPharma Dive · 06-16A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal InvestigationsSimply Wall St. · 05-11enGene Bladder Cancer Data Shows Promise, but Durability Questions RemainMarketBeat · 05-08
The file stays open
12 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice